Neurodevelopmental outcome after intrauterine red cell transfusion for parvovirus B19-induced fetal hydrops.
OBJECTIVE
To assess long term neurodevelopmental outcome of children after intrauterine intravascular red cell transfusion (JUT) for Parvovirus B19-induced fetal hydrops.


METHODS
Data of study children were investigated retrospectively. Neurodevelopmental evaluation was performed by appropriate standard tests (Griffiths, Snijders-Oomen, Kaufmann Assessment Battery for Children tests).


METHODS
Tertiary care university teaching hospital.


METHODS
Twenty children who had Parvovirus-induced fetal hydrops and intrauterine transfusion of packed red blood cells (IUT).


METHODS
Retrospective chart analysis and standard neurodevelopmental testing.


METHODS
Developmental quotient (DQ) and intelligence quotient (IQ) according to the age at testing.


RESULTS
Twenty survivors of Parvovirus B19-induced fetal hydrops successfully treated by IUT were followed until 13 months to nine years of age. On clinical follow up, no neurologic sequelae were evident. Neurodevelopmental scores of all children ranged within two standard deviations of a normal population (median 101, range 86-116) and exceeded one standard deviation in three children. There was no significant neurodevelopmental delay.


CONCLUSIONS
Children having survived successful IUT for Parvovirus B19-induced fetal anaemia and hydrops have a good neurodevelopmental prognosis. Our results support the use of IUT for correction of Parvovirus B19-induced fetal anaemia and subsequent hydrops.
Dembinski
J
J
Department of Neonatology, University of Bonn, Germany.
Haverkamp
F
F
Maara
H
H
Hansmann
M
M
Eis-Hübinger
A M
AM
Bartmann
P
P
D001805:Blood Transfusion, Intrauterine; D002648:Child; D002657:Child Development; D017707:Erythrocyte Transfusion / Q000379:methods*; D005260:Female; D005500:Follow-Up Studies; D005865:Gestational Age; D006801:Humans; D015160:Hydrops Fetalis / Q000821:virology*; D007360:Intelligence; D008297:Male; D015999:Multivariate Analysis; D010322:Parvoviridae Infections / Q000628:therapy*; D016732:Parvovirus B19, Human; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000628:therapy*; D011379:Prognosis; D012189:Retrospective Studies